If you have hit a tirzepatide plateau , restoring estrogen levels could re-sensitize your GLP-1 receptors and restart fat loss without increasing your tirzepatide dose
Extended-release niacin formulations may cause less glucose elevation than immediate-release products but carry a higher risk of hepatotoxicity
This article reviews current evidence on GLP-1 therapies and CKD progression, including biomarker data, clinical trial findings, and the potential role of these agents within evolving kidney disease treatment strategies
Intriguingly, observational studies demonstrate that patients with a higher BMI may have more severe psoriasis, and weight loss has been associated with improvements in PASI scores in patients treated with biological agents
By ensuring proper storage and transport of Ozempic, Wegovy and insulin supplies, stakeholders can uphold the promise of semaglutide and other sensitive therapies, improving outcomes for millions worldwide